Welcome to BioSeeker Group!

Apoptotic Therapeutics in Oncology - Where to Commercialize?

Additional Information

Published Date Nov 30, 2009
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 803
PDF Fact Sheet View Fact Sheet for the report Apoptotic Therapeutics in Oncology - Where to Commercialize? in PDF
Format PDF
Publisher BioSeeker Group
Product Line View All Available Cancer Highlights Reports

Availability: In stock

$2,450.00

Quick Overview

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It serves as an external commercial advocate for pharmaceutical companies’ portfolio planning and new product planning.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Apoptotic Therapeutics in Oncology - Where to Commercialize?.

    To find out more about Apoptotic Therapeutics in Oncology - Where to Commercialize?, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Apoptotic Therapeutics in Oncology - Where to Commercialize? is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This report comprises defined and up to date development strategies for 171 apoptotic drugs (519 projects) within the portfolio of 125 investigators, from Ceased to Pre-registration. The report extensively analyses 146 identified targets of apoptotic drugs, organized into 120 drug target profiles, and assesses them in 53 different cancer indications.

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It serves as an external commercial advocate for pharmaceutical companies’ portfolio planning and new product planning by:

Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report will also be an important part of creating and implementing a market development plan for any apoptotic drug in oncology to ensure that the optimal market conditions exist by the time the product is commercialized.

1 Executive Summary 3
2 About Cancer Highlights 4
3 Methodologies 6
4 Table of Contents 8
4.1 List of Figures 18
4.2 List of Tables 18
5 Introduction 27
5.1 The Scope of this Report 27
5.2 Definitions 31
5.3 Abbreviations 31
6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment 32
6.1 Drug Repositioning in Oncology 32
6.2 Introduction to Apoptotic Therapeutic Targets in Oncology 33
6.2.1 Auxiliary Transport Protein Activity Targets 36
6.2.2 Carboxy-lyase Activity Targets 37
6.2.3 Caspase Activator Activity Targets 38
6.2.4 Catalytic Activity Targets 39
6.2.5 Cell Adhesion Molecule Activity Targets 46
6.2.6 Cell Adhesion Molecule Activity Targets 47
6.2.7 Chaperone Activity Targets 50
6.2.8 Complement Activity Targets 54
6.2.9 Cysteine-type Peptidase Activity Targets 56
6.2.10 Cytokine Activity Targets 61
6.2.11 DNA Binding Targets 64
6.2.12 DNA topoisomerase Activity Targets 65
6.2.13 G-protein Coupled Receptor Activity Targets 68
6.2.14 Glutathione Transferase Activity Targets 72
6.2.15 Growth Factor Activity Targets 73
6.2.16 Growth Factor Binding Targets 74
6.2.17 GTPase Activity Targets 75
6.2.18 Hydrolase Activity Targets 82
6.2.19 Kinase Activity Targets 83
6.2.20 Kinase Regulator Activity Targets 91
6.2.21 Ligand-dependent Nuclear Receptor Activity Targets 93
6.2.22 Ligase Activity Targets 95
6.2.23 Lipid Kinase Activity Targets 99
6.2.24 Metallopeptidase Activity Targets 103
6.2.25 Molecular Function Unknown Targets 104
6.2.26 Motor Activity Targets 107
6.2.27 Oxidoreductase Activity Targets 108
6.2.28 Peptide Hormone Targets 110
6.2.29 Phosphoric Diester Hydrolase Activity Targets 111
6.2.30 Protein Binding Targets 113
6.2.31 Protein Serine/Threonine Kinase Activity Targets 115
6.2.32 Protein-Tyrosine Kinase Activity Targets 134
6.2.33 Receptor Activity Targets 136
6.2.34 Receptor Signaling Complex Scaffold Activity Targets 153
6.2.35 Receptor Signaling Protein Serine/Threonine Kinase Activity Targets 158
6.2.36 RNA Binding Targets 159
6.2.37 Serine-type Peptidase Activity Targets 160
6.2.38 Structural Constituent of Cytoskeleton Targets 161
6.2.39 Superoxide Dismutase Activity Targets 162
6.2.40 T cell Receptor Activity Targets 164
6.2.41 Transcription Factor Activity Targets 165
6.2.42 Transcription Regulator Activity Targets 173
6.2.43 Transferase Activity Targets 184
6.2.44 Translation Regulator Activity Targets 185
6.2.45 Transmembrane Receptor Activity Targets 187
6.2.46 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 191
6.2.47 Transporter Activity Targets 206
6.2.48 Ubiquitin-specific Protease Activity Targets 211
6.2.49 Other Drug Targets 213
6.3 The Cancer Genome Project and Apoptotic Therapeutic Targets in Oncology 215
6.3.1 Apoptotic Therapeutic Targets Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer 215
6.4 Structure-based Drug Design in Apoptotic Therapeutics is Stimulated by Available Structure Data on Biological Targets 218
6.5 Target-Target Interactions among Identified Apoptotic Therapeutics Targets in Oncology 222
6.6 The Drug-Target Interactome 227
6.7 Protein Expression Levels of Identified Apoptotic Therapeutic Targets in Oncology 232
6.8 Pathway Analysis of Cancer Apoptotic Therapeutic Targets 236
7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Profiles Identified in the Cancer Apoptotic Therapeutic Pipeline? 277
7.1 Terminated Drug Target Profiles of Cancer Apoptotic Drugs 287
7.2 Pre-Registration: New and Unique Drug Target Profiles of Apoptotic Therapeutics in Oncology 289
7.3 Phase III Clinical Development: New and Unique Drug Target Profiles of Apoptotic Therapeutics in Oncology 290
7.4 Phase II Clinical Development: New and Unique Drug Target Profiles of Apoptotic Therapeutics in Oncology 291
7.5 Phase I Clinical Development: New and Unique Drug Target Profiles of Apoptotic Therapeutics in Oncology 294
7.6 Preclinical Development: New and Unique Drug Target Profiles of Apoptotic Therapeutics in Oncology 298
7.7 Development Profiles of All Apoptotic Drugs in Oncology 301
8 Compound Strategies at Work: Competitive Benchmarking of Apoptotic Drugs in Oncology by Compound Type 312
8.1 Small Molecules 314
8.1.1 Background 314
8.1.2 Target Profiles of Small Molecular Drugs 315
8.2 Peptide/Protein Drugs 329
8.2.1 Background 329
8.2.2 Target Profiles of Peptide and Protein Drugs 330
8.3 Antibodies and Antibody-like Structures 334
8.3.1 Background 334
8.3.2 Target Profiles of Antibody Drugs 334
8.4 Nucleic Acid Therapies 337
8.4.1 Background 337
8.4.2 Target Profiles of Nucleic Acid Drugs 338
8.5 Gene Therapy 341
8.5.1 Background 341
8.5.2 Target Profiles of Gene Therapy Drugs 341
8.6 Drug Delivery and Nanotechnology 344
8.6.1 Background 344
8.6.2 Target Profiles of Reformulated Drugs 344
8.7 The Competition Through Close Mechanistic Approximation of Apoptotic Cancer Therapeutics 345
8.8 Compound Strategies based on Sub-Cellular Localization of Apoptotic Drug Targets in Oncology 349
9 Selecting Cancer Indications for Apoptotic Therapeutics 356
9.1 Acute Lymphocytic Leukemia 358
9.2 Acute Myelogenous Leukemia 359
9.3 Adrenal Cancer 361
9.4 B-cell Lymphoma 362
9.5 Basal Cell Cancer 364
9.6 Biliary Cancer 365
9.7 Bladder Cancer 366
9.8 Bone Cancer 367
9.9 Brain Cancer 368
9.10 Breast Cancer 370
9.11 Carcinoid 373
9.12 Cervical Cancer 374
9.13 Chronic Lymphocytic Leukemia 375
9.14 Chronic Myelogenous Leukemia 377
9.15 Colorectal Cancer 379
9.16 Endometrial Cancer 382
9.17 Ewing’s Sarcoma 383
9.18 Fallopian Tube Cancer 384
9.19 Fibro Sarcoma 385
9.20 Gastrointestinal Cancer (general) 386
9.21 Gastrointestinal Stomach Cancer 387
9.22 Gastrointestinal Stromal Cancer 389
9.23 Head and Neck Cancer 390
9.24 Hodgkin’s Lymphoma 392
9.25 Leiomyo Sarcoma 393
9.26 Leukemia (general) 394
9.27 Lipo Sarcoma 395
9.28 Liver Cancer 396
9.29 Lung Cancer (general) 397
9.30 Lymphoma (general) 398
9.31 Melanoma 400
9.32 Mesothelioma 402
9.33 Myelodysplastic Syndrome 403
9.34 Myeloma 405
9.35 Nasopharyngeal Cancer 407
9.36 non-Hodgkin’s Lymphoma 408
9.37 Non-Small Cell Lung Cancer 410
9.38 Oesophageal Cancer 413
9.39 Osteo Sarcoma 414
9.40 Ovarian Cancer 415
9.41 Pancreatic Cancer 418
9.42 Peritoneal Cancer 420
9.43 Prostate Cancer 421
9.44 Renal Cancer 424
9.45 Sarcoma (general) 426
9.46 Small Cell Lung Cancer 428
9.47 Soft Tissue Sarcoma 430
9.48 Squamous Cell Cancer 431
9.49 T-cell Lymphoma 432
9.50 Testicular Cancer 433
9.51 Thymoma Cancer 434
9.52 Thyroid Cancer 435
9.53 Unspecified Cancer Indication 436
10 Portfolio Planning: Competitive Benchmarking of Apoptotic Cancer Therapeutic Pipeline by Investigator 441
10.1 Abbott 445
10.2 AbGenomics 449
10.3 Access 451
10.4 Advanced Life Sciences 453
10.5 AEgera 455
10.6 Aeterna Zentaris 459
10.7 Aida Pharmaceuticals 463
10.8 Ambrilia Biopharma 466
10.9 Amgen 468
10.10 Anadys Pharmaceuticals 472
10.11 Anavex Life Sciences 474
10.12 Antisoma 477
10.13 Aphios 480
10.14 Apogenix 482
10.15 ApopLogic Pharmaceuticals 485
10.16 Arno Therapeutics 489
10.17 ArQule 491
10.18 Ascenta Therapeutics 495
10.19 Attenuon 498
10.20 Basilea Pharmaceutica 501
10.21 Bayer 504
10.22 BioAxone 508
10.23 Biogen Idec 510
10.24 BioInvent 512
10.25 BioLineRx 514
10.26 Bionovo 516
10.27 BioVex 518
10.28 Cancer Research Technology 520
10.29 Cephalon 522
10.30 ChemoCentryx 525
10.31 Chlorogen 527
10.32 Chroma Therapeutics 529
10.33 Cleveland BioLabs 531
10.34 CombinatoRx 533
10.35 Coronado Biosciences 535
10.36 Critical Outcome Technologies 538
10.37 Curis 540
10.38 Cyclacel 542
10.39 Cylene Pharmaceuticals 546
10.40 Cytochroma 549
10.41 Daewoong 551
10.42 Daiichi Sankyo 553
10.43 Dainippon Sumitomo Pharma 556
10.44 Eisai 559
10.45 Eleos 562
10.46 Eli Lilly 565
10.47 EntreMed 568
10.48 Enzon 571
10.49 EpiCept 574
10.50 Exelixis 579
10.51 Genentech 582
10.52 Genta 586
10.53 Genzyme 590
10.54 Gerolymatos 592
10.55 Geron 594
10.56 GlycoGenesys 597
10.57 GPC Biotech 600
10.58 Hoffmann-La Roche 602
10.59 Hollis-Eden Pharmaceuticals 606
10.60 Human Genome Sciences 608
10.61 Idera Pharmaceuticals 613
10.62 Infinity Pharmaceuticals 615
10.63 InNexus Biotechnology 618
10.64 Insmed 620
10.65 Intradigm 622
10.66 Introgen Therapeutics 624
10.67 Isis Pharmaceuticals 628
10.68 ISU ABXIS 631
10.69 Johnson & Johnson 633
10.70 Kalypsys 636
10.71 Keryx Biopharmaceuticals 639
10.72 Kyowa Hakko Kirin 642
10.73 Lorus Therapeutics 645
10.74 Medisyn Technologies 647
10.75 Merck & Co 650
10.76 MethylGene 652
10.77 NeoPharm 655
10.78 NIH – The US National Institute of Health 657
10.79 Nippon Shinyaku 659
10.80 Non-industrial Sources 661
10.81 Novacea 663
10.82 Novartis 666
10.83 Novelix 673
10.84 Novogen 675
10.85 Onconova 679
10.86 OSI Pharmaceuticals 681
10.87 OXiGENE 684
10.88 PanaGin 688
10.89 Patrys 691
10.90 Pfizer 693
10.91 Pharmacyclics 695
10.92 PharmaMar 700
10.93 Pharminox 704
10.94 Phytomedics 706
10.95 Pierre Fabre 708
10.96 QLT 710
10.97 Reata Pharmaceuticals 713
10.98 Regulon 716
10.99 Rosetta Genomics 719
10.100 Sanofi-Aventis 721
10.101 Santaris Pharma 724
10.102 Semafore Pharmaceuticals 726
10.103 Senesco Technologies 729
10.104 Sigma-Tau 731
10.105 SRI International 733
10.106 SuperGen 736
10.107 Switch Pharma 740
10.108 Symbiotec 742
10.109 Taxolog 744
10.110 Telik 747
10.111 Thallion Pharmaceuticals 750
10.112 Tigris Pharmaceuticals 753
10.113 TopoTarget 755
10.114 Tracon Pharmaceuticals 760
10.115 Trubion 763
10.116 UMN Pharma 765
10.117 ValiRx 767
10.118 Vascular Biogenics 770
10.119 Vertex Pharmaceuticals 772
10.120 VioQuest 775
10.121 Viragen 778
10.122 Viralytics 781
10.123 ViroTarg 784
10.124 VM Discovery 787
10.125 ZymoGenetics 790
11 Disclaimer 793
12 Drug Index 794
13 Company Index 799

4.1 List of Figures
Figure 1: Visualization of Target-Target Interactions among Apoptotic Drug Targets in Oncology 226
Figure 2: The Drug-Protein Interactome of Apoptotic Drugs –Large Clusters 229
Figure 3: The Drug-Protein Interactome of Apoptotic Drugs – Small Clusters 230
Figure 4: Head-to-Head Targeting Interactome of Apoptotic Drugs 231
Figure 5: Distribution of Compound Types among Apoptotic Drugs in Oncology 349
Figure 6: Primary Sub-cellular Localization of Drug Targets 350

4.2 List of Tables
Table 1: Head to Head Competition among Apoptopic Drugs in Oncology 27
Table 2: Overall Breakdown of the Included Apoptotic Pipeline by Cancer Indication and Stage of Development 27
Table 3: Overview of Drug Target Profile Themes 33
Table 4: Terminally Ceased Therapeutic Apoptotic Targets in Oncology 34
Table 5: Drug Targets of Apoptotic Drugs in Oncology Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census 216
Table 6: Identity of Apoptotic Drug Targets with Available Biological Structures 219
Table 7: Number of Target-Target Interactions among Apoptotic Drug Targets in Oncology 222
Table 8: Drug-Protein Interactome Clusters of Apoptotic Drugs in Oncology 227
Table 9: Apoptotic Drug Targets with Available Protein Expression Profiles 232
Table 10: Pathway Summary 236
Table 11: Drug Targets without any Identified Assigned Pathways 236
Table 12: Pathway Profiles According to BioCarta of Apoptotic Drug Targets in Oncology 238
Table 13: Pathway Profiles According to KEGG of Apoptotic Drug Targets in Oncology 256
Table 14: Pathway Profiles According to NetPath of Apoptotic Drug Targets in Oncology 273
Table 15: Number of Drug Target Profiles by their Highest Developmental Stage and Uniqueness 285
Table 16: Top Competitive Apoptotic Target Profiles in Oncology 285
Table 17: Terminated Drug Target Strategies of Apoptotic Drugs in Oncology 287
Table 18 New and Unique Apoptotic Target Strategies in Cancer Currently in Pre-Registration 289
Table 19: New and Unique Apoptotic Target Strategies in Cancer Currently in Phase III Clinical Development 290
Table 20: New and Unique Apoptotic Target Strategies in Cancer Currently in Phase II Clinical Development 291
Table 21: The Competition Through Close Mechanistic Approximation Between Phase II Apoptotic Drugs in Oncology 293
Table 22 New and Unique Apoptotic Target Strategies in Cancer Currently in Phase I Clinical Development 294
Table 23: The Competition Through Close Mechanistic Approximation Between Phase I Apoptotic Drugs in Oncology 296
Table 24: New and Unique Apoptotic Target Strategies in Oncology Currently in Preclinical Development 298
Table 25: The Competition Through Close Mechanistic Approximation Between Preclinical Apoptotic Drugs in Oncology 300
Table 26: The Progression, Maturity and Competitive Comparison of Apoptotic Drug Target Profiles in Cancer Drug Development 301
Table 27: Overview of Compound Strategy Competition Among Apoptotic Drugs in Oncology 313
Table 28: Overview of the Competitive Landscape of Apoptotic Small Molecular Drugs in Oncology 315
Table 29: The Competition Through Close Mechanistic Approximation between Apoptotic Small Molecule Drugs in Oncology 316
Table 30: Competitive Comparison of Target Profiles of Apoptotic Small Molecule Drugs in Oncology 318
Table 31: Overview of the Competitive Landscape of Peptide Based Apoptotic Drugs in Oncology 330
Table 32: The Competition Through Close Mechanistic Approximation between Apoptotic Peptide Based Drugs in Oncology 330
Table 33: Competitive Comparison of Target Profiles of Apoptotic Peptide Based Drugs in Oncology 331
Table 34: Overview of the Competitive Landscape of Apoptotic Protein Based Drugs in Oncology 332
Table 35: The Competition Through Close Mechanistic Approximation between Apoptotic Protein Based Drugs in Oncology 332
Table 36: Competitive Comparison of Apoptotic Protein Based Drugs in Oncology 333
Table 37: Overview of the Competitive Landscape of Apoptotic Antibody Drugs in Oncology 334
Table 38: The Competition Through Close Mechanistic Approximation between Apoptotic Antibody Drugs in Oncology 335
Table 39: Competitive Comparison of Target Profiles of Apoptotic Antibody Drugs in Oncology 335
Table 40: Overview of the Competitive Landscape of Apoptotic Nucleic Acid Therapy Drugs in Oncology 338
Table 41: The Competition Through Close Mechanistic Approximation between Apoptotic Nucleic Acid Therapy Drugs in Oncology 338
Table 42: Competitive Comparison of Target Profiles of Apoptotic Nucleic Acid Drugs in Oncology 339
Table 43: Vectors in Gene Therapy 341
Table 44: Overview of the Competitive Landscape of Apoptotic Gene Therapy Drugs in Oncology 341
Table 45: The Competition Through Close Mechanistic Approximation between Apoptotic Gene Therapy Drugs in Oncology 342
Table 46: Competitive Comparison of Target Profiles of Apoptotic Gene Therapy Based Drugs in Oncology 342
Table 47:Overview of the Competitive Landscape of Reformulated Apoptotic Drugs in Oncology 344
Table 48: Competitive Comparison of Target Profiles of Reformulated Apoptotic Drugs in Oncology 344
Table 49: The Competition Through Close Mechanistic Approximation Among All Apoptotic Drugs in Oncology 345
Table 50: Compound Strategies based on Sub-Cellular Localization of Apoptotic Drug Targets in Oncology 350
Table 51: Competitive Summary of Apoptotic Drugs by Cancer Indication 356
Table 52: Drug Target Profiles of Apoptotic Drugs for the Treatment of Acute Lymphocytic Leukemia 358
Table 53: Drug Target Profiles of Apoptotic Drugs for the Treatment of Acute Myelogenous Leukemia 359
Table 54: The Competition through Close Mechanistic Approximation between Acute Myelogenous Drugs 360
Table 55: Drug Target Profiles of Apoptotic Drugs for the Treatment of Adrenal Cancer 361
Table 56: Drug Target Profiles of Apoptotic Drugs for the Treatment of B-cell Lymphoma 362
Table 57: The Competition through Close Mechanistic Approximation between B-cell Lymphoma Drugs 363
Table 58: Drug Target Profiles of Apoptotic Drugs for the Treatment of Basal Cell Cancer 364
Table 59: Drug Target Profiles of Apoptotic Drugs for the Treatment of Biliary Cancer 365
Table 60: Drug Target Profiles of Apoptotic Drugs for the Treatment of Bladder Cancer 366
Table 61: Drug Target Profiles of Apoptotic Drugs for the Treatment of Bone Cancer 367
Table 62: Drug Target Profiles of Apoptotic Drugs for the Treatment of Brain Cancer 368
Table 63: Drug Target Profiles of Apoptotic Drugs for the Treatment of Breast Cancer 370
Table 64: The Competition through Close Mechanistic Approximation between Breast Cancer Drugs 372
Table 65: Drug Target Profiles of Apoptotic Drugs for the Treatment of Carcinoid 373
Table 66: Drug Target Profiles of Apoptotic Drugs for the Treatment of Cervical Cancer 374
Table 67: Drug Target Profiles of Apoptotic Drugs for the Treatment of Chronic Lymphocytic Leukemia 375
Table 68: The Competition through Close Mechanistic Approximation between Chronic Lymphocytic Leukemia Drugs 376
Table 69: Drug Target Profiles of Apoptotic Drugs for the Treatment of Chronic Myelogenous Leukemia 377
Table 70: The Competition through Close Mechanistic Approximation between Chronic Myelogenous Leukemia Drugs 378
Table 71: Drug Target Profiles of Apoptotic Drugs for the Treatment of Colorectal Cancer 379
Table 72: The Competition through Close Mechanistic Approximation between Colorectal Cancer Drugs 380
Table 73: Drug Target Profiles of Apoptotic Drugs for the Treatment of Endometrial Cancer 382
Table 74: Drug Target Profiles of Apoptotic Drugs for the Treatment of Ewing’s Sarcoma 383
Table 75: Drug Target Profiles of Apoptotic Drugs for the Treatment of Fallopian Tube Cancer 384
Table 76: Drug Target Profiles of Apoptotic Drugs for the Treatment of Fibro Sarcoma 385
Table 77: Drug Target Profiles of Apoptotic Drugs for the Treatment of Gastrointestinal Cancer (general) 386
Table 78: Drug Target Profiles of Apoptotic Drugs for the Treatment of Gastrointestinal Stomach Cancer 387
Table 79: Drug Target Profiles of Apoptotic Drugs for the Treatment of Gastrointestinal Stromal Cancer 389
Table 80: Drug Target Profiles of Apoptotic Drugs for the Treatment of Head and Neck Cancer 390
Table 81: Drug Target Profiles of Apoptotic Drugs for the Treatment of Hodgkin’s Lymphoma 392
Table 82: Drug Target Profiles of Apoptotic Drugs for the Treatment of Leiomyo Sarcoma 393
Table 83: Drug Target Profiles of Apoptotic Drugs for the Treatment of Leukemia (general) 394
Table 84: Drug Target Profiles of Apoptotic Drugs for the Treatment of Lipo Sarcoma 395
Table 85: Drug Target Profiles of Apoptotic Drugs for the Treatment of Liver Cancer 396
Table 86: Drug Target Profiles of Apoptotic Drugs for the Treatment of Lung Cancer (general) 397
Table 87: Drug Target Profiles of Apoptotic Drugs for the Treatment of Lymphoma (general) 398
Table 88: Drug Target Profiles of Apoptotic Drugs for the Treatment of Melanoma 400
Table 89: The Competition through Close Mechanistic Approximation between Melanoma Cancer Drugs 401
Table 90: Drug Target Profiles of Apoptotic Drugs for the Treatment of Mesothelioma 402
Table 91: Drug Target Profiles of Apoptotic Drugs for the Treatment of Myelodysplastic Syndrome 403
Table 92: The Competition through Close Mechanistic Approximation between Myelodysplastic Syndrome Drugs 404
Table 93: Drug Target Profiles of Apoptotic Drugs for the Treatment of Myeloma 405
Table 94: The Competition through Close Mechanistic Approximation between Myeloma Drugs 406
Table 95: Drug Target Profiles of Apoptotic Drugs for the Treatment of Nasopharyngeal Cancer 407
Table 96: Drug Target Profiles of Apoptotic Drugs for the Treatment of non-Hodgkin’s Lymphoma 408
Table 97: The Competition through Close Mechanistic Approximation between non-Hodgkin’s Lymphoma Drugs 409
Table 98: Drug Target Profiles of Apoptotic Drugs for the Treatment of Non-Small Cell Lung Cancer 410
Table 99: The Competition through Close Mechanistic Approximation between Non-Small Cell Lung Cancer Drugs 412
Table 100: Drug Target Profiles of Apoptotic Drugs for the Treatment of Oesophageal Cancer 413
Table 101: Drug Target Profiles of Apoptotic Drugs for the Treatment of Osteo Sarcoma 414
Table 102: Drug Target Profiles of Apoptotic Drugs for the Treatment of Ovarian Cancer 415
Table 103: The Competition through Close Mechanistic Approximation between Ovarian Cancer Drugs 417
Table 104: Drug Target Profiles of Apoptotic Drugs for the Treatment of Pancreatic Cancer 418
Table 105: The Competition through Close Mechanistic Approximation between Pancreatic Cancer Drugs 419
Table 106: Drug Target Profiles of Apoptotic Drugs for the Treatment of Peritoneal Cancer 420
Table 107: Drug Target Profiles of Apoptotic Drugs for the Treatment of Prostate Cancer 421
Table 108: The Competition through Close Mechanistic Approximation between Prostate Cancer Drugs 423
Table 109: Drug Target Profiles of Apoptotic Drugs for the Treatment of Renal Cancer 424
Table 110: The Competition through Close Mechanistic Approximation between Renal Cancer Drugs 425
Table 111: Drug Target Profiles of Apoptotic Drugs for the Treatment of Sarcoma (general) 426
Table 112: The Competition through Close Mechanistic Approximation between Sarcoma (general) Drugs 427
Table 113: Drug Target Profiles of Apoptotic Drugs for the Treatment of Small Cell Lung Cancer 428
Table 114: The Competition through Close Mechanistic Approximation between Small Cell Lung Cancer Drugs 429
Table 115: Drug Target Profiles of Apoptotic Drugs for the Treatment of Soft Tissue Sarcoma 430
Table 116: Drug Target Profiles of Apoptotic Drugs for the Treatment of Squamous Cell Cancer 431
Table 117: Drug Target Profiles of Apoptotic Drugs for the Treatment of T-cell Lymphoma 432
Table 118: Drug Target Profiles of Apoptotic Drugs for the Treatment of T-cell Lymphoma 432
Table 119: Drug Target Profiles of Apoptotic Drugs for the Treatment of Testicular Cancer 433
Table 120: Drug Target Profiles of Apoptotic Drugs for the Treatment of Thymoma Cancer 434
Table 121: Drug Target Profiles of Apoptotic Drugs for the Treatment of Thyroid Cancer 435
Table 122: Drug Target Profiles of Apoptotic Drugs for the Treatment of Unspecified Cancer Indication 436
Table 123: The Competition through Close Mechanistic Approximation between Unspecified Cancer Indication Drugs 439
Table 124: Abbott’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 445
Table 125: AbGenomics’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 449
Table 126: Access’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 451
Table 127: Advanced Life Sciences’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 453
Table 128: AEgera’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 455
Table 129: Aeterna Zentaris’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 459
Table 130: Aida Pharmaceuticals’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 463
Table 131: Ambrilia Biopharma’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 466
Table 132: Amgen’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 468
Table 133: Anadys Pharmaceuticals’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 472
Table 134: Anavex Life Sciences’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 474
Table 135: Antisoma’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 477
Table 136: Aphios’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 480
Table 137: Apogenix’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 482
Table 138: ApopLogic Pharmaceuticals’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 485
Table 139: Arno Therapeutics’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 489
Table 140: ArQule’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 491
Table 141: Ascenta Therapeutics’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 495
Table 142: Attenuon’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 498
Table 143: Basilea Pharmaceutica’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 501
Table 144: Bayer’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 504
Table 145: BioAxone’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 508
Table 146: Biogen Idec’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 510
Table 147: BioInvent’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 512
Table 148: BioLineRx’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 514
Table 149: Bionovo’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 516
Table 150: BioVex’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 518
Table 151: Cancer Research Technology’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 520
Table 152: Cephalon’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 522
Table 153: ChemoCentryx’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 525
Table 154: Chlorogen’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 527
Table 155: Chroma Therapeutics’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 529
Table 156: Cleveland BioLabs’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 531
Table 157: CombinatoRx’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 533
Table 158: Coronado Biosciences’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 535
Table 159: Critical Outcome Technologies’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 538
Table 160: Curis’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 540
Table 161: Cyclacel’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 542
Table 162: Cylene Pharmaceuticals’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 546
Table 163: Cytochroma’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 549
Table 164: Daewoong’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 551
Table 165: Daiichi Sankyo’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 553
Table 166: Dainippon Sumitomo Pharma’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 556
Table 167: Eisai’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 559
Table 168: Eleos’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 562
Table 169: Eli Lilly’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 565
Table 170: EntreMed’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 568
Table 171: Enzon’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 571
Table 172: EpiCept’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 574
Table 173: Exelixis’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 579
Table 174: Genentech’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 582
Table 175: Genta’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 586
Table 176: Genzyme’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 590
Table 177: Gerolymatos’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 592
Table 178: Geron’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 594
Table 179: GlycoGenesys’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 597
Table 180: GPC Biotech’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 600
Table 181: Hoffmann-La Roche’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 602
Table 182: Hollis-Eden Pharmaceuticals’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 606
Table 183: Human Genome Sciences’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 608
Table 184: Idera Pharmaceuticals’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 613
Table 185: Infinity Pharmaceuticals’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 615
Table 186: InNexus Biotechnology’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 618
Table 187: Insmed’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 620
Table 188: Intradigm’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 622
Table 189: Introgen Therapeutics’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 624
Table 190: Isis Pharmaceuticals’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 628
Table 191: ISU ABXIS’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 631
Table 192: Johnson & Johnson’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 633
Table 193: Kalypsys’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 636
Table 194: Keryx Biopharmaceuticals’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 639
Table 195: Kyowa Hakko Kirin’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 642
Table 196: Lorus Therapeutics’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 645
Table 197: Medisyn Technologies’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 647
Table 198: Merck & Co’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 650
Table 199: MethylGene’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 652
Table 200: NeoPharm’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 655
Table 201: NIH’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 657
Table 202: Nippon Shinyaku’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 659
Table 203: Non-industrial source’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 661
Table 204: Novacea’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 663
Table 205: Novartis’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 666
Table 206: Novelix’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 673
Table 207: Novogen’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 675
Table 208: Onconova’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 679
Table 209: OSI Pharmaceuticals’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 681
Table 210: OXiGENE’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 684
Table 211: PanaGin’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 688
Table 212: Patrys’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 691
Table 213: Pfizer’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 693
Table 214: Pharmacyclics’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 695
Table 215: PharmaMar’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 700
Table 216: Pharminox’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 704
Table 217: Phytomedics’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 706
Table 218: Pierre Fabre’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 708
Table 219: QLT’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 710
Table 220: Reata Pharmaceuticals’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 713
Table 221: Regulon’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 716
Table 222: Rosetta Genomics’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 719
Table 223: Sanofi-Aventis’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 721
Table 224: Santaris Pharma’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 724
Table 225: Semafore Pharmaceuticals’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 726
Table 226: Senesco Technologies’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 729
Table 227: Sigma-Tau’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 731
Table 228: SRI International’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 733
Table 229: SuperGen’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 736
Table 230: Switch Phar’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 740
Table 231: Symbiotec’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 742
Table 232: Taxolog’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 744
Table 233: Telik’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 747
Table 234: Thallion Pharmaceuticals’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 750
Table 235: Tigris Pharmaceuticals’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 753
Table 236: TopoTarget’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 755
Table 237: Tracon Pharmaceuticals’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 760
Table 238: Trubion’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 763
Table 239: UMN Pharma’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 765
Table 240: ValiRx’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 767
Table 241: Vascular Biogenics’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 770
Table 242: Vertex Pharmaceuticals’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 772
Table 243: VioQuest’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 775
Table 244: Viragen’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 778
Table 245: Viralytics’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 781
Table 246: ViroTarg’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 784
Table 247: VM Discovery’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 787
Table 248: ZymoGenetics’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 790

This report includes 125 investigators plus their collaborators:
Abbott
AbGenomics
Access
Advanced Life Sciences
AEgera
Aeterna Zentaris
Aida Pharmaceuticals
Ambrilia Biopharma
Amgen
Anadys Pharmaceuticals
Anavex Life Sciences
Antisoma
Aphios
Apogenix
ApopLogic Pharmaceuticals
Arno Therapeutics
ArQule
Ascenta Therapeutics
Attenuon
Basilea Pharmaceutica
Bayer
BioAxone
Biogen Idec
BioInvent
BioLineRx
Bionovo
BioVex
Cancer Research Technology
Cephalon
ChemoCentryx
Chlorogen
Chroma Therapeutics
Cleveland BioLabs
CombinatoRx
Coronado Biosciences
Critical Outcome Technologies
Curis
Cyclacel
Cylene Pharmaceuticals
Cytochroma
Daewoong
Daiichi Sankyo
Dainippon Sumitomo Pharma
Eisai
Eleos
Eli Lilly
EntreMed
Enzon
EpiCept
Exelixis
Genentech
Genta
Genzyme
Gerolymatos
Geron
GlycoGenesys
GPC Biotech
Hoffmann-La Roche
Hollis-Eden Pharmaceuticals
Human Genome Sciences
Idera Pharmaceuticals
Infinity Pharmaceuticals
InNexus Biotechnology
Insmed
Intradigm
Introgen Therapeutics
Isis Pharmaceuticals
ISU ABXIS
Johnson & Johnson
Kalypsys
Keryx Biopharmaceuticals
Kyowa Hakko Kirin
Lorus Therapeutics
Medisyn Technologies
Merck & Co
MethylGene
NeoPharm
NIH
Nippon Shinyaku
Non-industrial source
Novacea
Novartis
Novelix
Novogen
Onconova
OSI Pharmaceuticals
OXiGENE
PanaGin
Patrys
Pfizer
Pharmacyclics
PharmaMar
Pharminox
Phytomedics
Pierre Fabre
QLT
Reata Pharmaceuticals
Regulon
Rosetta Genomics
Sanofi-Aventis
Santaris Pharma
Semafore Pharmaceuticals
Senesco Technologies
Sigma-Tau
SRI International
SuperGen
Switch Pharma
Symbiotec
Taxolog
Telik
Thallion Pharmaceuticals
Tigris Pharmaceuticals
TopoTarget
Tracon Pharmaceuticals
Trubion
UMN Pharma
ValiRx
Vascular Biogenics
Vertex Pharmaceuticals
VioQuest
Viragen
Viralytics
ViroTarg
VM Discovery
ZymoGenetics
This report includes 171 apoptotic drugs in oncology. From Ceased to Pre-registration ones.
A shortlist of drugs included are:
2-methoxyestradiol
ABT-263
AEG-35156
afutuzumab
alvocidib
Apomab
ARQ-197
AS-1411
atiprimod dimaleate
ATN-224
belinostat
BZL-101
canfosfamide hydrochloride
CBLC-102
cenersen
cintredekin besudotox
combretastatin A-4 prodrug
conatumumab
CS-1008
dulanermin
GCS-100LE
GRN-163L
HE-3235
idronoxil
indisulam
INGN-241
INGN-401
ISIS-23722
kahalalide F
lonaprisan
lumiliximab
mapatumumab
MGCD-0103
MKC-1
motexafin gadolinium
oblimersen sodium
panobinostat
PARP inhibitors
PAT-SC1
patupilone
PCI-24781
plitidepsin
quarfloxacin
retaspimycin
Rh-Apo2L
sagopilone
seliciclib
tigapotide triflutate
TLN-232
triciribine
TRU-016
voreloxin
VX-944
XL-647

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Apoptotic Therapeutics in Oncology - Where to Commercialize?.
    To find out more about Apoptotic Therapeutics in Oncology - Where to Commercialize?, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Apoptotic Therapeutics in Oncology - Where to Commercialize? is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Cancer Highlights' category:


The Drug Target Atlas of Apoptotic Drugs in Oncology
First in place, BioSeeker has surveyed apoptopic drugs in oncology and identified 119 drug targets, belonging to 114 drugs. This report, The Drug Target Atlas of Apoptopic Drugs in Oncology, is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of new apoptopic drugs in oncology. Learn More


Currently Druggable in Melanoma: A Drug Target Competitive Analysis
This report is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of melanoma drugs. Learn More

Other selected research from the 'Oncology' category:


Colorectal Cancer Drug Pathway Analyzer
There are today at least 516 targeted molecular therapies known to affect more than 252 specific intracellular signaling pathways for the treatment of colorectal cancer. The rational for this plethora of treatment strategies is based on our increasing understanding of the 313 drug targets that are included in this drug-pathway analyzing tool. No less than 301 of these have been recorded with mutations and 60 drug targets have mutations which have been causally implicated in cancer. Learn More


Triple Analysis: Pancreatic Cancer, Angiogenesis and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in Pancreatic Cancer and by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors. Learn More